| Literature DB >> 32369445 |
Natalia I Dmitrieva1, Avram D Walts1, Dai Phuong Nguyen1, Alex Grubb1, Xue Zhang2, Xujing Wang2, Xianfeng Ping1, Hui Jin1, Zhen Yu1, Zu-Xi Yu3, Dan Yang1, Robin Schwartzbeck1, Clifton L Dalgard4,5,6, Beth A Kozel7, Mark D Levin7, Russell H Knutsen7, Delong Liu7, Joshua D Milner8, Diego B López8, Michael P O'Connell8, Chyi-Chia Richard Lee9, Ian A Myles10, Amy P Hsu10, Alexandra F Freeman10, Steven M Holland10, Guibin Chen1, Manfred Boehm1.
Abstract
There are more than 7000 described rare diseases, most lacking specific treatment. Autosomal-dominant hyper-IgE syndrome (AD-HIES, also known as Job's syndrome) is caused by mutations in STAT3. These patients present with immunodeficiency accompanied by severe nonimmunological features, including skeletal, connective tissue, and vascular abnormalities, poor postinfection lung healing, and subsequent pulmonary failure. No specific therapies are available for these abnormalities. Here, we investigated underlying mechanisms in order to identify therapeutic targets. Histological analysis of skin wounds demonstrated delayed granulation tissue formation and vascularization during skin-wound healing in AD-HIES patients. Global gene expression analysis in AD-HIES patient skin fibroblasts identified deficiencies in a STAT3-controlled transcriptional network regulating extracellular matrix (ECM) remodeling and angiogenesis, with hypoxia-inducible factor 1α (HIF-1α) being a major contributor. Consistent with this, histological analysis of skin wounds and coronary arteries from AD-HIES patients showed decreased HIF-1α expression and revealed abnormal organization of the ECM and altered formation of the coronary vasa vasorum. Disease modeling using cell culture and mouse models of angiogenesis and wound healing confirmed these predicted deficiencies and demonstrated therapeutic benefit of HIF-1α-stabilizing drugs. The study provides mechanistic insights into AD-HIES pathophysiology and suggests potential treatment options for this rare disease.Entities:
Keywords: Cardiovascular disease; Extracellular matrix; Monogenic diseases; Therapeutics; Vascular Biology
Mesh:
Substances:
Year: 2020 PMID: 32369445 PMCID: PMC7410079 DOI: 10.1172/JCI135490
Source DB: PubMed Journal: J Clin Invest ISSN: 0021-9738 Impact factor: 14.808